【摘要】：目的探討在大鼠心臟移植缺血再灌注損傷(Ischemia-Reperfusion injury,IRI)過程中血清和糖皮質(zhì)激素調(diào)節(jié)激酶1(Serum-and glucocorticoid regulated kinase 1,SGK-1)的表達(dá)變化;研究SGK-1是否參與心臟移植IRI所引起的心肌細(xì)胞凋亡;分析地塞米松能否改變SGK-1的表達(dá),能否起到保護(hù)心臟移植IRI心肌細(xì)胞的作用。方法1、通過大鼠頸部異位心臟移植方法,建立大鼠同異基因心臟移植組(Syngeneic heart transplantation SHT/Allogeneic heart transplantation AHT,SHT組Lewis(Lew:RT11)移植到Lewis(Lew:RT11)大鼠);AHT組:Wistar(WF:RT1u)移植到Lewis(Lew:RT11)大鼠)IRI模型,部分供體在心臟移植前預(yù)先用不同濃度的地塞米松(0.05,0.5,and 2mg/BWkg)預(yù)先處理。2、通過RT-PCR方法,分析SGK-1 mRNA在AHT/SHT組IRI過程中表達(dá)變化。3、利用免疫組化學(xué)方法(Immunohistochemistry)、蛋白印記方法(Western Blot)、免疫熒光共定位染色法方法(Double Immunofluorescent Staining),分析在AHT/SHT組IRI過程中SGK-1表達(dá)變化、組織分布、細(xì)胞定位情況。4、利用免疫熒光共定位染色法方法,研究分析SGK-1表達(dá)變化與免疫細(xì)胞、細(xì)胞凋亡相關(guān)Marker之間的關(guān)系。5、通過HE染色方法,觀察大鼠心臟移植術(shù)后急性排斥反應(yīng)及心臟移植IRI心肌細(xì)胞的病理變化過程。6、通過統(tǒng)計(jì)學(xué)法方,綜合分析實(shí)驗(yàn)數(shù)據(jù)并得出統(tǒng)計(jì)學(xué)結(jié)論。結(jié)果1、大鼠AHT/SHT組IRI模型中,通過RT-PCR、蛋白印記等實(shí)驗(yàn)方法,發(fā)現(xiàn)SGK-1在mRNA及蛋白質(zhì)水平都發(fā)生了表達(dá)改變。在術(shù)后1 h,mRNA及蛋白質(zhì)表達(dá)開始升高,6 h升高明顯,12 h達(dá)到表達(dá)高峰,24 h后恢復(fù)到接近6 h表達(dá)水平。2、通過免疫組化結(jié)果,我們分別在AHT/SHT組移植物的心肌細(xì)胞上觀察到SGK-1陽性細(xì)胞的表達(dá),通過免疫熒光共定位染色結(jié)果,進(jìn)一步明確了SGK-1在心肌細(xì)胞中表達(dá),且表達(dá)趨勢與蛋白印記結(jié)果具有一致性。3、通過免疫熒光共定位染色結(jié)果,我們發(fā)現(xiàn)SGK-1與急性排斥相關(guān)Marker之間沒有明顯的共定位現(xiàn)象。而與凋亡Marker之間存在共定位現(xiàn)象。4、通過蛋白印記、免疫組化、免疫熒光等實(shí)驗(yàn)分析發(fā)現(xiàn):地塞米松預(yù)處理后SGK-1的表達(dá)明顯比未用地塞米松處理組高。5、HE染色顯示:地塞米松預(yù)處理后心臟移植IRI所引起的心肌細(xì)胞損傷明顯減少。結(jié)論1、SGK-1在心臟移植后表達(dá)上調(diào),且主要定位于心肌細(xì)胞中。2、SGK-1參與了心臟移植IRI引起的心肌細(xì)胞凋亡過程,并起到抗心肌細(xì)胞凋亡的作用,其可能機(jī)制與NF-kB凋亡途徑相關(guān)。對SGK-1的深入研究可為今后抑制心臟移植IRI心肌細(xì)胞凋亡提供有效的作用靶點(diǎn)。3、地塞米松能夠增加SGK-1的表達(dá)并起到減少心肌細(xì)胞損傷的作用。這將可能為減少IRI后心肌細(xì)胞的凋亡提供一個(gè)新的理論依據(jù)并將成為新的治療靶點(diǎn)。
[Abstract]:Objective to investigate the changes of serum and glucocorticoid regulated kinase 1 (Serum-and glucocorticoid regulated kinase 1) SGK-1 expression during ischemia-reperfusion injury (Ischemia-Reperfusion injury,IRI) in rat heart transplantation. To study whether SGK-1 is involved in cardiomyocyte apoptosis induced by cardiac transplantation IRI and whether dexamethasone can change the expression of SGK-1 and protect the cardiac myocytes from heart transplantation IRI. Methods 1. By using the method of cervical heterotopic heart transplantation in rats, Lewis (Lew:RT11) in (Syngeneic heart transplantation SHT/Allogeneic heart transplantation AHT,SHT group was transplanted to Lewis (Lew:RT11) group. AHT group (: Wistar (WF:RT1u) was transplanted into Lewis (Lew:RT11) rat) IRI model. Some donors were pretreated with different concentrations of dexamethasone (0.05U 0.5 and 2mg/BWkg) before heart transplantation. 2. RT-PCR method was used. The expression of SGK-1 mRNA in IRI of AHT/SHT group was analyzed. 3. The (Immunohistochemistry), protein imprinting method, (Western Blot), immunofluorescence co-localization staining method and (Double Immunofluorescent Staining), method were used to analyze the expression of IRI in AHT/SHT group. The changes of SGK-1 expression, tissue distribution and cellular localization during IRI in AHT/SHT group were analyzed. 4. Immunofluorescence co-localization staining method was used to study the changes of SGK-1 expression and immune cells. The relationship between apoptosis-related Marker. 5. By means of HE staining, the pathological process of acute rejection and cardiac allograft IRI cardiomyocytes after cardiac transplantation in rats was observed. Comprehensive analysis of experimental data and draw statistical conclusions. Results 1. In the IRI model of rat AHT/SHT group, the expression of SGK-1 in mRNA and protein levels was changed by RT-PCR, protein imprinting and other experimental methods. The expression of mRNA and protein began to increase at 1 h after operation, increased significantly at 6 h, reached the peak at 12 h, and recovered to nearly 6 h after 24 h. We observed the expression of SGK-1 positive cells in cardiac myocytes of AHT/SHT group, and further clarified the expression of SGK-1 in cardiac myocytes by immunofluorescence co-localization staining. The expression trend was consistent with the result of protein imprinting. 3. By immunofluorescence co-localization staining, we found that there was no obvious co-localization between SGK-1 and Marker associated with acute rejection. The expression of SGK-1 was significantly higher after dexamethasone pretreatment than that without dexamethasone treatment. HE staining showed that cardiac injury induced by IRI was significantly reduced after dexamethasone preconditioning. Conclusion 1 the expression of SGK-1 was up-regulated after cardiac transplantation and was mainly located in cardiac myocytes. 2SGK-1 participated in the process of cardiomyocyte apoptosis induced by cardiac transplantation IRI and played an anti-apoptosis role in cardiac myocytes. The possible mechanism is related to the apoptosis pathway of NF-kB. The further study of SGK-1 can provide an effective target for inhibiting cardiomyocyte apoptosis in cardiac transplantation IRI in the future. 3. Dexamethasone can increase the expression of SGK-1 and reduce myocardial cell injury. This may provide a new theoretical basis for the reduction of cardiomyocyte apoptosis after IRI and become a new therapeutic target.
【學(xué)位授予單位】：南通大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R654.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 夏求明 ,臧旺福;心臟移植進(jìn)展[J];醫(yī)療保健器具;2000年Z1期

2 ;人造心臟可能取代心臟移植[J];醫(yī)學(xué)情報(bào)工作;2000年04期

3 ;細(xì)胞注入取代心臟移植[J];浙江中醫(yī)雜志;2001年08期

4 郭尚耘;供心的摘取及保護(hù)在心臟移植中的作用[J];福建醫(yī)藥雜志;2001年01期

5 王銘輝,蘇逢錫,宋爾衛(wèi),孫培吾;小鼠心臟移植技術(shù)的改良[J];廣東醫(yī)學(xué);2001年01期

6 齊弘煒,朱朗標(biāo),高長青,李伯君;中國心臟移植的現(xiàn)狀與未來[J];醫(yī)學(xué)與哲學(xué);2001年10期

7 馮強(qiáng),梁宏立,倪一鳴;基因工程在心臟移植中的應(yīng)用[J];中華胸心血管外科雜志;2002年01期

8 賀榜福;心臟移植的現(xiàn)狀與展望[J];廣西醫(yī)學(xué);2002年12期

9 朱樹勛;臺灣心臟移植之現(xiàn)況[J];嶺南心血管病雜志;2002年04期

10 魏崢,余國膺;臺灣心臟移植——臺北振興醫(yī)院經(jīng)驗(yàn)[J];中國心臟起搏與心電生理雜志;2002年03期

相關(guān)會議論文 前10條

1 陳良萬;陳道中;林峰;王齊敏;黃忠耀;邱罕凡;曹華;黃雪珊;吳錫階;戴小福;;提高心臟移植近期療效初探[A];第八屆華東六省一市胸心血管外科學(xué)術(shù)會議論文匯編[C];2005年

2 陳昊;王春生;張穎;洪濤;趙強(qiáng);宋凱;楊守國;姜楨;;老年患者心臟移植的臨床經(jīng)驗(yàn)[A];第八屆華東六省一市胸心血管外科學(xué)術(shù)會議論文匯編[C];2005年

3 宋來鳳;趙紅;王紅月;呂鳳英;李莉;劉蕾;;42例心臟移植病例受體心臟的病理學(xué)觀察[A];中華醫(yī)學(xué)會心血管病學(xué)分會第八次全國心血管病學(xué)術(shù)會議匯編[C];2006年

4 廖崇先;陳良萬;陳道中;吳錫階;單忠貴;;125例心臟移植病人的中長期隨訪[A];中華醫(yī)學(xué)會第七次全國胸心血管外科學(xué)術(shù)會議暨2007中華醫(yī)學(xué)會胸心血管外科青年醫(yī)師論壇論文集心血管外科分冊[C];2007年

5 錢仲h，

本文編號：2349674